Nutriband (NASDAQ:NTRB – Get Free Report) and Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Profitability
This table compares Nutriband and Prelude Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutriband | -560.89% | -133.22% | -114.00% |
| Prelude Therapeutics | N/A | -121.16% | -84.93% |
Earnings & Valuation
This table compares Nutriband and Prelude Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutriband | $2.14 million | 26.18 | -$10.48 million | ($3.07) | -1.50 |
| Prelude Therapeutics | $7.00 million | 16.53 | -$127.17 million | ($1.47) | -1.25 |
Nutriband has higher earnings, but lower revenue than Prelude Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Nutriband has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
Institutional & Insider Ownership
19.7% of Nutriband shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Comparatively, 63.9% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for Nutriband and Prelude Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutriband | 1 | 1 | 1 | 0 | 2.00 |
| Prelude Therapeutics | 1 | 0 | 2 | 0 | 2.33 |
Nutriband presently has a consensus price target of $13.00, suggesting a potential upside of 182.61%. Prelude Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 117.39%. Given Nutriband’s higher probable upside, equities analysts plainly believe Nutriband is more favorable than Prelude Therapeutics.
Summary
Prelude Therapeutics beats Nutriband on 10 of the 14 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
